Tannock IF - Search Results

1

A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.

Sridhar SS, Mackenzie MJ, Hotte SJ, Mukherjee SD, Tannock IF, Murray N, Kollmannsberger C, Haider MA, Chen EX, Halford R, Wang L, Ivy SP, Moore MJ. Sridhar SS, et al. Among authors: tannock if. Invest New Drugs. 2013 Aug;31(4):1008-15. doi: 10.1007/s10637-013-9931-1. Epub 2013 Jan 26. Invest New Drugs. 2013. PMID: 23354849 Clinical Trial.

2

Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the Princess Margaret Hospital experience.

Choo R, Tannock I. Choo R, et al. Cancer. 1991 Nov 15;68(10):2120-4. doi: 10.1002/1097-0142(19911115)68:10<2120::aid-cncr2820681005>3.0.co;2-7. Cancer. 1991. PMID: 1913449

3

How American oncologists treat breast cancer: an assessment of the influence of clinical trials.

Belanger D, Moore M, Tannock I. Belanger D, et al. J Clin Oncol. 1991 Jan;9(1):7-16. doi: 10.1200/JCO.1991.9.1.7. J Clin Oncol. 1991. PMID: 1985172

4

Are treatment strategies of urologic oncologists influenced by the opinions of their colleagues?

Moore MJ, O'Sullivan B, Tannock IF. Moore MJ, et al. Among authors: tannock if. Br J Cancer. 1990 Dec;62(6):988-91. doi: 10.1038/bjc.1990.422. Br J Cancer. 1990. PMID: 2257231 Free PMC article.

5

How expert physicians would wish to be treated if they had genitourinary cancer.

Moore MJ, O'Sullivan B, Tannock IF. Moore MJ, et al. Among authors: tannock if. J Clin Oncol. 1988 Nov;6(11):1736-45. doi: 10.1200/JCO.1988.6.11.1736. J Clin Oncol. 1988. PMID: 3054004 Clinical Trial.

6

Quality assessment of clinical trials in bladder cancer.

Tannock I, Moore M. Tannock I, et al. Eur Urol. 1988;14 Suppl 1:46. doi: 10.1159/000473045. Eur Urol. 1988. PMID: 3181246 No abstract available.

7

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J. Moore MJ, et al. Among authors: tannock if. J Clin Oncol. 1994 Apr;12(4):689-94. doi: 10.1200/JCO.1994.12.4.689. J Clin Oncol. 1994. PMID: 7512127 Clinical Trial.

8

A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.

Moore MJ, Iscoe N, Tannock IF. Moore MJ, et al. Among authors: tannock if. J Urol. 1993 Oct;150(4):1131-4. doi: 10.1016/s0022-5347(17)35706-3. J Urol. 1993. PMID: 8371371 Clinical Trial.

9

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Tannock IF, et al. J Clin Oncol. 1996 Jun;14(6):1756-64. doi: 10.1200/JCO.1996.14.6.1756. J Clin Oncol. 1996. PMID: 8656243 Clinical Trial.

10

Overview of Canadian trials in hormonally resistant prostate cancer.

Moore MJ, Tannock IF. Moore MJ, et al. Among authors: tannock if. Semin Oncol. 1996 Dec;23(6 Suppl 14):15-9. Semin Oncol. 1996. PMID: 8996579 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

496 results

Search Page

Filters